Changjiang Commercial Daily News ● Changjiang Commercial Daily reporter Jiang Chuya
Further enrich and improve the product matrix, and innovate the head of the Pharmaceutical Head Company, Kangyuan Pharmaceutical (600557.SH) to inject Chinese medicine companies.
On November 7, Kangyuan Pharmaceutical issued an announcement that the company intends to acquire the controlling shareholder of 270 million yuan (hereinafter referred to as"Kangyuan Group") Holding subsidiary Jiangsu Zhongxin Pharmaceutical Co., Ltd. (hereinafter referred to as "Zhongxin Pharmaceutical") 100%equity.
Kangyuan Pharmaceutical said that the company can continue to empower Sino -Singapore Pharmaceutical with the platform, resources, funds and sales channels of the listed company, and intends to pass it in the future by proper time.The method of absorbing the new pharmaceuticals into the listed company enables the R & D team, pipelines and platforms of Sino -Singapore Pharmaceuticals into listed companies as a whole to achieve integrated and efficient management, accelerate the industrialization of research and development results, and accelerate the commercialization of products.
Kangyuan Pharmaceutical has continuously increased investment in R & D to enhance the competitiveness and innovation capabilities of products.From 2020 to the first half of 2024, the research and development costs of Kangyuan Pharmaceuticals were 380 million yuan, 499 million yuan, 606 million yuan, 772 million yuan, and 339 million yuan, and the cumulative four -year and a half years of research and development costs were 2.596 billion yuan.At the same time, the companys R & D expense ratio has maintained a lead in the industry.From 2020 to 2023, the R & D expenses of Kangyuan Pharmaceuticals were 12.6%, 13.7%, 13.9%, and 15.8%, respectively, showing a steady rise.In the first half of 2024, R & D expenses were 339 million yuan, and the R & D cost rate was 15%.
In terms of business performance, in the third quarter of 2024, the company realized operating income of 3.110 billion yuan, a year -on -year decrease of 11.06%, and the net profit attributable to motherGrowing 2.18%.As of June 30, 2024, Kangyuan Pharmaceutical had a total of 2.28 billion yuan in monetary funds and trading financial assets, and there was no short -term or long -term borrowing.
Gao premium acquisition of rich biopharmaceutical research and development pipelines
On November 7, Kangyuan Pharmaceutical announced announced thatIn order to further enrich the companys biopharmaceutical research and development pipelines, improve the companys product matrix, enhance the companys research and development capabilities, and create an influential and competitive biopharmaceutical innovation research and development platform, help the company to achieve long -term and sustainable development, it is planned to use its own funds of 270 millionYuan acquisition of 100%equity of Sino -Singapore Pharmaceuticals, the companys controlling shareholder Kangyuan Group holds 70%of the equity of Sino -Singapore Pharmaceutical, corresponding to the transfer price of 189 million yuan.
The company will pay 60%of the first payment of Kangyuan Group, that is, 113.4 million yuan, the remaining 40%, that is, 75.6 million yuan will be paid in installments after the listing permit of the corresponding pipeline of China -Singapore Pharmaceuticals will be paid.Essence
According to reports, Sino -Singapore Pharmaceutical is committed to reorganizing human cytokine, fusion protein and antibody biopharmaceuticals to focus on the development of metabolic diseases and nervous system diseases.At present, the company has obtained 6 clinical approval of 4 innovative medicines, all of which have entered the clinical stage.Among the four core pipelines under research, two of them are GLP-1 products currently hot. Therefore, from the perspective of Kangyuan Pharmaceutical, whether it is continuing to develop independently or in the future pipeline BD, the product has good good ones.Market expectations.
It is worth noting that China-Singapore Pharmaceutical has been in a loss since its establishment. The net assets audited by September 30, 2024 were -423 million yuan.In the first three quarters of 2024, the companys operating income was about 3.3776 million yuan, the net profit was about 64.8028 million yuan, and the net cash flow generated by operating activities was -37.7728 million yuan.
It is worth noting that shortly after the above announcement was released, the Shanghai Stock Exchange issued a supervision letter of supervision of related transactions to Kangyuan Pharmaceutical, involving objects including companies, directors, supervisors, senior managementPersonnel, controlling shareholders and actual controllers.
From the perspective of the performance of the capital market, the second day when the acquisition of 100%equity plan of Sino -Singapore Pharmaceuticals equity plan, Kangyuan Pharmaceuticals stock price opened high, and it was close to the daily limit board in the afternoon. As of November 8thDaily closed, the companys stock price was reported at 16.31 yuan/share, an increase of 7.51%, with a total market value of 9.489 billion yuan.
Increase R & D and enhances innovation competitiveness
Kangyuan Pharmaceuticals current main product line focuses on respiratory and virus infectionsSexual diseases, gynecological diseases, cardiovascular and cerebrovascular diseases, orthopedic diseases and other areas of traditional Chinese medicine.Jin Zhen oral solution, thermal poisoning injection, and ginkgo -pyrethrodidinee amine.
Data show that Kangyuan Pharmaceutical is a large -scale Chinese medicine enterprise integrating the research and development, production, and sales of categories, national key high -tech enterprises, national technology innovation demonstration enterprises, and Chinese pharmaceutical industry 100Strong enterprises, fifth in the top ten Chinese medicine companies in the country, the top 20 of Chinese pharmaceutical companies, and more than 5,000 employees.With a number of national scientific research platforms such as "National Key Laboratory of the National Key Laboratory of Chinese Medicine Pharmaceutical Process and Intelligent Manufacturing Technology" and "Sino -Pharmaceutical Intelligent Manufacturing Technology National Local Joint Engineering Research Center".Laboratory "(top -ranking in the field of pharmaceuticals).
Kangyuan Pharmaceuticals, as the leading Chinese medicine leader, has focused on research and development as the first strategy, innovated the concept of the gangster, and continued to obtain new breakthroughs.The number of valid invention patents and undertaking major national scientific research projects has a leading position in the industry.
In the first half of the year, Kangyuan Pharmaceutical has gained a lot in research and development, and continued to promote the development of new products. Three varieties of Chinese medicines were submitted to drug listing (NDA) varieties, and phase III clinical research was completed.There are 2 varieties, 2 clinical trial approval notices; 1 pharmaceutical innovation drugs have completed the stage II clinical cases, and 2 clinical trial approval notices are obtained; 3 drug registration certificates are obtained by chemical drugs; biopharmaceutical development is carried outPhase I clinical varieties.During the reporting period, it actively promoted the protection of intellectual property rights and nearly 20 authorized invention patents to build a moat for the companys technology and product innovation.
Kangyuan Pharmaceutical said on the investor interactive platform on November 1 that there are 112 varieties (48 categories A and 64 categories B) in the companys products on November 1st.The medical insurance directory includes 25 exclusive varieties such as thermal poisoning injection, ginkgo -pyrethrodidine injector injection, Jin Zhen oral liquid, apricot cough particles, ginseng kidney tablets, Guizhi Poria capsules and other exclusive varieties.
Kangyuan Pharmaceutical has always regarded R & D and innovation as the core strategy of enterprise development, and continuously increases investment in R & D to enhance the competitiveness and innovation capabilities of products.
Data show that from 2020 to the first half of 2024, the research and development costs of Kangyuan Pharmaceuticals were 380 million yuan, 499 million yuan, 606 million yuan, 772 million yuan, 339 million yuan,The total research and development costs of four and a half years have accumulated 2.596 billion yuan.
At the same time, the R & D expense ratio of Kangyuan Pharmaceutical has maintained a leading leader in the industry.From 2020 to 2023, the companys R & D cost rates were 12.6%, 13.7%, 13.9%, and 15.8%, respectively, showing a steady rise.In the first half of 2024, R & D expenses were 339 million yuan, and the R & D cost rate was 15%.
In terms of performance, from 2021 to 2023, the revenue of Kangyuan Pharmaceutical has maintained a growth trend. In the past three years, the companys revenue increased by 20.34%, 19.25%and 11.88%year -on -year.In 2023, Kangyuan Pharmaceutical also existed the best answer sheet ever, with operating income of 4.868 billion yuan and net profit of 537 million yuan.
But due to the pressure of the core category collection, the "cold" in the first half of 2024, the operating income and net profit of Kangyuan Pharmaceutical have doubled in the first four years.In the first half of the year, the companys operating income was 2.26 billion yuan, a year -on -year decrease of 11.48%; net profit was 265 million yuan, a decrease of 3.73%year -on -year.
As the policy supports the innovation and development of the Chinese medicine industry, Kangyuan Pharmaceuticals performance has gradually rebounded.The companys operating income in the first three quarters was 3.110 billion yuan, a year -on -year decrease of 11.06%; net profit was 357 million yuan, an increase of 2.18%year -on -year.
